Literature DB >> 33464728

Ileocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study.

Nicholas J Talley1,2, James L Alexander3, Marjorie M Walker2,4, Michael P Jones2,5, Luisa W Hugerth6, Lars Engstrand6, Lars Agréus7, Nicholas Powell2,3, Anna Andreasson5,8,9.   

Abstract

INTRODUCTION: Histopathological alterations in the ileum and colon in irritable bowel syndrome (IBS) are controversial, and normal values are poorly established. We hypothesized that changes in mucosal immune cells characterize IBS and key changes in immune composition are associated with the mucosa-associated microbiota (MaM).
METHODS: A nested case-control study (48 IBS and 106 controls included) from 745 colonoscopy participants in a random population sample. Intraepithelial lymphocytes (IELs)/100 enterocytes and eosinophils/5 nonoverlapping high-power fields counted; mast cells identified by immunocytochemistry (CD117)/5 high-power fields. Paneth cells quantified per 5 crypts. 16S rRNA gene amplicon sequencing performed on available sigmoid MaM, n = 55 and fecal microbiota, n = 20. Microbiota profiles compared between samples with high and low IEL counts.
RESULTS: IBS had increased IELs in the terminal ileum (relative risk ratio = 1.70, 95% confidence interval 1.08-2.76, P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS-diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13-3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. DISCUSSION: A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Entities:  

Year:  2020        PMID: 33464728     DOI: 10.14309/ctg.0000000000000296

Source DB:  PubMed          Journal:  Clin Transl Gastroenterol        ISSN: 2155-384X            Impact factor:   4.488


  3 in total

1.  Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field.

Authors:  Marc E Rothenberg; Shawna K B Hottinger; Nirmala Gonsalves; Glenn T Furuta; Margaret H Collins; Nicholas J Talley; Kathryn Peterson; Calies Menard-Katcher; Macie Smith; Ikuo Hirano; Robert M Genta; Mirna Chehade; Sandeep K Gupta; Jonathan M Spergel; Seema S Aceves; Evan S Dellon
Journal:  J Allergy Clin Immunol       Date:  2021-12-22       Impact factor: 10.793

2.  Immune responses in the irritable bowel syndromes: time to consider the small intestine.

Authors:  Grace L Burns; Nicholas J Talley; Simon Keely
Journal:  BMC Med       Date:  2022-03-31       Impact factor: 8.775

Review 3.  A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.

Authors:  Baha Moshiree; Joel J Heidelbaugh; Gregory S Sayuk
Journal:  Adv Ther       Date:  2022-07-22       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.